Safety and Efficacy Study of Urokinase for the Treatment of Diabetic Foot Syndrome and Critical Limb Ischemia

Inclusion Criteria: * age 18 years or older * angiopathic or angioneuropathic critical limb ischemia (at least Wagner-Armstrong stadium II) * participation in the August-1 Register * revascularization not possible or residual ischemia after revascularization * persisting ulcerations despite antibiosis, adjustment of blood glucose levels and debridement * expected further hospitalization for at least 3 weeks (pressure relief and antibiosis) * fibrinogen \>= 4g/l * signed informed consent Exclusion Criteria: * life expectancy \< 1 year * prior major amputation * planned major amputation * prior therapy of the current episode of diabetic foot syndrome with urokinase (except in cases of revascularization when the duration between the intervention and randomization must not exceed 7 days) * mechanical heart valve substitute * cerebral event with CT-detectable changes in the last 3 months * non-remediated proliferation retinopathy * uncontrolled hypertension (systolic \>180 mmg, diastolic \>100 mmHg) * hemorrhagic diathesis (spontaneous quick \< 50%, spontaneous PTT \> 40 s, thrombocytes \< 100 Gpt/l) * gastrointestinal bleeding or ulcers in the last 4 weeks * prior reverse bypass operation * contraindications against therapy with urokinase acc. to the SMPc * concurrent participation in another clinical trial * insufficient compliance * pregnancy